Kilitch Net Income From Continuing Ops vs Other Operating Expenses Analysis

KILITCH Stock   315.60  4.95  1.59%   
Kilitch Drugs financial indicator trend analysis is infinitely more than just investigating Kilitch Drugs Limited recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Kilitch Drugs Limited is a good investment. Please check the relationship between Kilitch Drugs Net Income From Continuing Ops and its Other Operating Expenses accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kilitch Drugs Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Net Income From Continuing Ops vs Other Operating Expenses

Net Income From Continuing Ops vs Other Operating Expenses Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Kilitch Drugs Limited Net Income From Continuing Ops account and Other Operating Expenses. At this time, the significance of the direction appears to have strong relationship.
The correlation between Kilitch Drugs' Net Income From Continuing Ops and Other Operating Expenses is 0.65. Overlapping area represents the amount of variation of Net Income From Continuing Ops that can explain the historical movement of Other Operating Expenses in the same time period over historical financial statements of Kilitch Drugs Limited, assuming nothing else is changed. The correlation between historical values of Kilitch Drugs' Net Income From Continuing Ops and Other Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income From Continuing Ops of Kilitch Drugs Limited are associated (or correlated) with its Other Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Operating Expenses has no effect on the direction of Net Income From Continuing Ops i.e., Kilitch Drugs' Net Income From Continuing Ops and Other Operating Expenses go up and down completely randomly.

Correlation Coefficient

0.65
Relationship DirectionPositive 
Relationship StrengthSignificant

Net Income From Continuing Ops

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Kilitch Drugs Limited. It is also known as Kilitch Drugs overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.
Most indicators from Kilitch Drugs' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Kilitch Drugs Limited current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kilitch Drugs Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
As of now, Kilitch Drugs' Tax Provision is increasing as compared to previous years. The Kilitch Drugs' current Issuance Of Capital Stock is estimated to increase to about 40.5 M, while Selling General Administrative is projected to decrease to under 25 M.
 2021 2022 2023 2024 (projected)
Gross Profit488.0M648.4M620.5M310.3M
Total Revenue1.1B1.4B1.5B889.7M

Kilitch Drugs fundamental ratios Correlations

0.6-0.60.810.830.530.190.360.47-0.170.420.610.2-0.490.31-0.130.580.690.760.430.770.74-0.180.61-0.140.02
0.60.060.710.210.710.60.10.46-0.53-0.050.75-0.050.190.72-0.250.320.730.320.70.250.550.20.580.09-0.09
-0.60.06-0.11-0.870.170.29-0.26-0.2-0.15-0.43-0.23-0.210.980.22-0.15-0.520.08-0.52-0.09-0.9-0.190.61-0.10.54-0.09
0.810.71-0.110.350.770.440.180.4-0.20.310.50.310.030.36-0.190.260.980.60.30.330.820.320.470.26-0.05
0.830.21-0.870.350.11-0.140.40.36-0.040.40.460.06-0.840.09-0.010.670.180.650.340.910.4-0.580.49-0.470.09
0.530.710.170.770.110.560.040.72-0.66-0.240.25-0.250.270.570.120.070.80.060.620.210.830.090.280.0-0.1
0.190.60.290.44-0.140.56-0.690.41-0.46-0.340.29-0.060.370.560.090.170.5-0.090.39-0.020.310.290.070.2-0.02
0.360.1-0.260.180.40.04-0.69-0.060.10.390.230.05-0.25-0.01-0.320.10.130.440.090.240.18-0.140.48-0.12-0.04
0.470.46-0.20.40.360.720.41-0.06-0.85-0.560.23-0.48-0.170.420.440.340.35-0.220.720.510.63-0.420.08-0.650.13
-0.17-0.53-0.15-0.2-0.04-0.66-0.460.1-0.850.79-0.260.68-0.16-0.57-0.38-0.11-0.220.45-0.82-0.22-0.430.31-0.010.55-0.13
0.42-0.05-0.430.310.4-0.24-0.340.39-0.560.790.140.72-0.37-0.27-0.460.150.230.88-0.450.230.040.220.350.48-0.16
0.610.75-0.230.50.460.250.290.230.23-0.260.14-0.04-0.140.39-0.470.380.450.510.60.350.41-0.060.69-0.050.01
0.2-0.05-0.210.310.06-0.25-0.060.05-0.480.680.72-0.04-0.12-0.21-0.240.150.280.57-0.690.0-0.170.620.00.53-0.1
-0.490.190.980.03-0.840.270.37-0.25-0.17-0.16-0.37-0.14-0.120.29-0.2-0.480.23-0.42-0.06-0.86-0.10.7-0.030.6-0.12
0.310.720.220.360.090.570.56-0.010.42-0.57-0.270.39-0.210.29-0.020.40.410.020.580.10.20.130.420.01-0.27
-0.13-0.25-0.15-0.19-0.010.120.09-0.320.44-0.38-0.46-0.47-0.24-0.2-0.02-0.02-0.22-0.480.070.250.01-0.33-0.68-0.530.06
0.580.32-0.520.260.670.070.170.10.34-0.110.150.380.15-0.480.4-0.020.160.390.260.550.11-0.240.51-0.30.36
0.690.730.080.980.180.80.50.130.35-0.220.230.450.280.230.41-0.220.160.50.270.150.780.450.450.38-0.07
0.760.32-0.520.60.650.06-0.090.44-0.220.450.880.510.57-0.420.02-0.480.390.5-0.060.470.340.110.610.32-0.08
0.430.7-0.090.30.340.620.390.090.72-0.82-0.450.6-0.69-0.060.580.070.260.27-0.060.430.55-0.480.41-0.480.04
0.770.25-0.90.330.910.21-0.020.240.51-0.220.230.350.0-0.860.10.250.550.150.470.430.43-0.630.21-0.610.04
0.740.55-0.190.820.40.830.310.180.63-0.430.040.41-0.17-0.10.20.010.110.780.340.550.43-0.140.34-0.10.04
-0.180.20.610.32-0.580.090.29-0.14-0.420.310.22-0.060.620.70.13-0.33-0.240.450.11-0.48-0.63-0.140.010.84-0.16
0.610.58-0.10.470.490.280.070.480.08-0.010.350.690.0-0.030.42-0.680.510.450.610.410.210.340.010.180.03
-0.140.090.540.26-0.470.00.2-0.12-0.650.550.48-0.050.530.60.01-0.53-0.30.380.32-0.48-0.61-0.10.840.18-0.23
0.02-0.09-0.09-0.050.09-0.1-0.02-0.040.13-0.13-0.160.01-0.1-0.12-0.270.060.36-0.07-0.080.040.040.04-0.160.03-0.23
Click cells to compare fundamentals

Kilitch Drugs Account Relationship Matchups

Kilitch Drugs fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets1.4B2.0B2.1B2.2B2.4B1.7B
Short Long Term Debt Total126.1M148.0M204.3M221.9M316.5M332.3M
Other Current Liab21.0M22.3M15.8M17.7M16.8M15.9M
Total Current Liabilities219.7M733.2M692.8M688.7M642.2M369.3M
Total Stockholder Equity1.2B1.3B1.4B1.5B1.8B1.2B
Property Plant And Equipment Net383.3M733.8M537.5M473.6M481.2M293.0M
Net Debt98.5M23.6M104.2M23.5M127.4M68.2M
Cash27.6M124.5M100.1M198.5M189.1M99.1M
Non Current Assets Total870.5M1.2B957.4M931.2M940.7M749.4M
Non Currrent Assets Other3.6M4.4M(68.8M)6.2M7.2M6.8M
Cash And Short Term Investments305.7M488.5M572.4M592.0M690.2M474.6M
Net Receivables(341K)(522K)414.3M542.9M632.6M664.2M
Common Stock Shares Outstanding15.4M15.5M15.6M15.6M15.9M15.4M
Liabilities And Stockholders Equity1.4B2.0B2.1B2.2B2.4B1.7B
Non Current Liabilities Total3.9M3.8M2.8M683K1.7M1.6M
Inventory55.6M35.9M52.9M20.4M93.1M49.7M
Other Current Assets196.6M279.3M20.0M28.8M43.5M41.3M
Total Liab223.6M737.0M695.5M689.4M643.9M357.3M
Total Current Assets557.9M803.6M1.1B1.3B1.5B916.0M
Accumulated Other Comprehensive Income(195.5M)209.1M254.1M274.8M287.1M301.5M
Short Term Debt126.1M148.0M204.3M221.9M316.5M332.3M
Common Stock153.6M154.3M154.9M155.8M160.8M150.7M
Accounts Payable71.0M536.5M428.7M408.7M255.9M177.6M
Current Deferred Revenue16.9M42.9M58.9M55.9M53.1M59.2M
Retained Earnings481.4M518.2M591.8M696.3M842.3M624.5M
Short Term Investments278.1M364.0M472.3M393.5M501.1M378.1M
Intangible Assets502K1.5M2.3M204.8M4.4M4.2M
Other Liab3.9M3.8M2.8M683K614.7K584.0K
Net Tangible Assets954.5M1.1B1.2B1.3B1.5B1.1B
Other Assets13.3M17.2M19.7M19.8M1.00.95
Property Plant Equipment383.3M733.8M464.0M473.6M544.6M309.3M
Short Long Term Debt126.1M148.0M204.3M221.9M316.5M332.3M
Good Will227.5M219.1M210.6M202.2M193.8M189.4M
Net Invested Capital1.3B1.4B1.6B1.7B2.1B1.7B
Net Working Capital338.1M70.5M448.3M575.3M817.8M499.5M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Kilitch Stock

Balance Sheet is a snapshot of the financial position of Kilitch Drugs Limited at a specified time, usually calculated after every quarter, six months, or one year. Kilitch Drugs Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Kilitch Drugs and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Kilitch currently owns. An asset can also be divided into two categories, current and non-current.